From First Symptom to Diagnosis: How Long It Takes and Who Waits Longest

For most people, a cancer diagnosis does not come out of nowhere. It comes at the end of a stretch of weeks or months that starts with a first symptom. In ten health systems with broadly similar resources, the typical time from first symptom of bowel cancer to the start of treatment ranged from 77 days in one to 168 in another.^[1] How long that stretch lasts depends heavily on the cancer, the health system and who the person is.

Symptoms can be vague and come and go. Appointments can be hard to get. A first set of tests can be reassuring and wrong, and specialist services can be full. This study looks at what population data show about those intervals around the world, who waits longest, and what is known about whether the waiting matters. It does not and cannot say what any one person's symptoms mean.

The road to diagnosis has measurable stretches, and each has its own causes

For years, research on "delay" was hard to compare because studies defined their start and end points differently. In 2012 an international group of researchers published the Aarhus statement, a consensus set of definitions and methods for studying the time before a cancer diagnosis.^[4] Most of the studies in this article use its terms:

• Patient interval: from first noticing a symptom to first seeing a health professional about it.
• Primary care interval: from that first consultation to referral to a specialist.
• Diagnostic interval: from first consultation to the date of diagnosis, covering both primary care and hospital tests.
• Treatment interval: from diagnosis to the start of treatment.
• Total interval: from first symptom to start of treatment.

These terms describe time, not fault. Measuring the intervals is also harder than it sounds. When researchers tested questionnaires built on the Aarhus guidance, people were least certain about dates in exactly the situations that matter most. As the authors put it, "Uncertainty was greatest in the context of multiple or vague symptoms, and potentially ambiguous time-points."^[5] The World Health Organization's guide to early diagnosis makes the same point from a policy angle: the barriers that lengthen these intervals can start with people and their carers or with health systems, and "Addressing delays in cancer diagnosis and inaccessible treatment is therefore critical in all settings for cancer control."^[6]

The same cancer can take twice as long to reach treatment in one health system as another

The largest international comparison of these intervals is Module 4 of the International Cancer Benchmarking Partnership (ICBP). It surveyed people newly diagnosed with cancer, their GPs and their cancer specialists in ten jurisdictions in Australia, Canada, Denmark, Norway, Sweden and the UK, and added information from records, for people diagnosed mostly between 2013 and 2015.

For bowel (colorectal) cancer, the median time from first symptom to start of treatment ranged from 77 to 168 days between jurisdictions. The patient interval ranged from 21 to 49 days, the primary care interval from 0 to 12 days, and the diagnostic interval from 27 to 76 days.^[1] Of the three intervals before treatment, the diagnostic interval, which includes hospital tests, varied most between jurisdictions.

Other cancers in the same programme show the same pattern:

Two cautions apply. The surveys reached only a minority of those diagnosed: the lung study included 2,143 of 10,203 eligible people (21.0%).^[7] And medians say little about the people who wait longest, for whom the lung and breast results show the widest gaps between countries.

Most people are referred after one or two GP visits, but about one in five need three or more

England has unusually deep primary care data, so it serves as a worked example. In a national audit of 13,035 people with 18 cancers diagnosed in 2009–10, 58% were referred after one consultation and 25% after two. A further 9%, 4% and 5% needed three, four, or five or more consultations. The median primary care interval rose with the number of visits: 0 days after one visit, 15 after two, 34 after three, 47 after four and 97 after five or more.^[10] So the number of GP consultations before referral is a simple, trackable measure of how quickly cancer is recognised.

A later audit of 17,042 people diagnosed in 2014 in 439 English practices found a median primary care interval of 5 days and a median diagnostic interval of 40 days (interquartile range 15–86 days).^[11] Scotland's audit for the same year found a median diagnostic interval of 30 days, longer for people in the most remote areas.^[12]

The most recent national figure comes from England's 2025 National Cancer Patient Experience Survey, published in July 2026. Of 30,698 respondents who answered and could remember, 78.1% said they had spoken to a health professional at their GP practice only once or twice about the problems caused by their cancer before diagnosis. That leaves about 22% who did so three or more times. The figure has barely moved, from 77.0% in 2021 to 78.6% in 2024 and 78.1% in 2025, although the survey's publisher flags the 2021–2025 change as statistically significant.^[2]

The type of cancer makes the biggest difference. Cancers with a clear warning sign are usually referred quickly; cancers with vague symptoms shared with common conditions are not. In 2025, 91.9% of respondents with breast cancer had spoken to their practice only once or twice, against 68.6% with lung cancer and 60.2% with blood (haematological) cancers.^[2] The 2010 survey showed the same pattern: three or more visits were reported by 7.4% of people with breast cancer and 10.1% with melanoma, but 41.3% with pancreatic cancer and 50.6% with multiple myeloma.^[13]

Younger people and people from minority ethnic groups are more likely to need repeated GP visits before referral

The same 2010 survey of 41,299 people in England looked at who was more likely to need three or more visits once the type of cancer was taken into account. People aged 16–24 had 2.12 times the odds of people aged 65–74. Asian respondents had 1.73 times the odds and Black respondents 1.83 times the odds of White respondents. Women had 1.28 times the odds of men, and for bladder cancer the gap between women and men was larger still (2.31 times the odds).^[13]

The 2025 survey suggests the gaps by ethnicity and age have not closed. These are unadjusted figures, so part of each gap reflects differences in which cancers each group tends to have. Even so, the share who spoke to their practice only once or twice was 79.2% among White respondents, against 68.0% among Asian respondents and 60.7% among Black respondents. It was 54.7% among the 86 respondents aged 16–24, against 84.1% among those aged 85 and over. By area deprivation, it was 73.6% in the most deprived fifth and 79.6% in the least deprived.^[2] Repeat visits matter for more than time. An analysis of 73,462 respondents to two English surveys found that people with three or more pre-referral consultations reported worse experiences of their later cancer care on 10 of 12 questions, with a dose-response pattern: the more visits, the worse the reported experience.^[14]

These surveys do not explain the gaps, but they locate them in the process of recognising and investigating cancer, not in the person. When GPs in England's 2014 audit judged that an avoidable delay had happened, which they did for 22% of cases, they attributed it to patient factors in 26% of instances, clinician factors in 28% and system factors in 34%.^[11]

Worry about wasting the doctor's time varies between countries more than symptom knowledge does

The ICBP tested whether knowledge explains hesitation with a telephone survey of 19,079 adults aged 50 and over in six countries. Symptom awareness was no lower in the UK and Denmark, which then had poorer survival, than in the other countries. What differed was perceived barriers. In the UK, 34% said worry about wasting the doctor's time would put them off, against 21% in Canada, 14% in Australia, 12% in Denmark, 11% in Norway and 9% in Sweden. Awareness that cancer risk rises with age was also lower in the UK (14%), Canada (13%) and Australia (16%) than in Sweden (38%).^[3]

In the ICBP countries, median patient intervals for breast cancer were 3 to 29 days.^[8] In low- and middle-income countries they are often much longer, for reasons well beyond knowledge. A 2023 meta-analysis of 50 studies covering 18,014 women with breast cancer in low- and middle-income countries found the longest typical patient intervals in studies from the Middle East (3–4 months), then South-East Asia (2 months), Africa (1–2 months), and Latin America and Eastern Europe (1 month each). Longer intervals were linked to lower socio-economic status, illiteracy, low knowledge about cancer, fear, negative beliefs about cancer and low social support.^[15] A 2024 review of 21 studies in 14 such countries found breast cancer took longer to diagnose than to treat. It also found "inconsistency in terminology and benchmarks for defining delays".^[16] The late stage at which many breast cancers are found in sub-Saharan Africa is covered in our study of stage at diagnosis.

Shorter journeys are linked to better outcomes for some cancers, and the evidence is messy

A 2015 systematic review of 209 studies across all cancers found that differences in design and quality meant "Heterogeneity precluded definitive findings". The cancers with the most reports of shorter time to diagnosis being linked to better outcomes were breast, colorectal, head and neck and testicular cancer and melanoma. The authors still judged it reasonable to assume faster diagnosis is likely to bring benefits, which vary between cancers.^[17]

Part of the difficulty is that people whose illness is most obvious and most serious are often diagnosed fastest, which can make short intervals look linked to worse outcomes. An ICBP analysis of 6,162 people with breast, colorectal, lung or ovarian cancer found a U-shaped pattern for the hospital part of the journey. The odds of an advanced rather than localised cancer fell from the first day onwards, then rose again after about three and a half months.^[18] The authors concluded that some cancers may progress even within regulated diagnostic timeframes.

The evidence is clearer once a cancer has been diagnosed. A 2020 meta-analysis of 34 studies covering 1,272,681 people found that, for surgery, each four-week delay to treatment was linked to a 6% to 8% higher hazard of death (hazard ratios 1.06 to 1.08). Even a four-week delay was associated with higher mortality across surgery, drug treatment and radiotherapy for seven cancers.^[19] These are associations from observational studies, not proof that a delay caused any one person's outcome.

Health systems can shorten these intervals. In 2008 Denmark introduced standardised cancer patient pathways, which let GPs refer suspected cancer into fast-track routes. In GP survey and registry data on 12,558 people, the median diagnostic interval was 17 days shorter after the pathways were introduced than before. People who were not referred into a pathway, however, had a slightly longer interval than during the rollout.^[20] A follow-up study estimated that lead-time bias, where earlier diagnosis only appears to lengthen survival by starting the clock sooner, explained about 13% of the improvement in one-year survival over the same period.^[21] How survival compares between countries is covered in our international survival study.

What the evidence asks of us

The data point to changes for services, commissioners and policymakers, not advice for individuals.

• Build fast routes for vague symptoms, not only alarm symptoms. People with blood, lung, pancreatic and brain cancers are more likely to need repeated GP visits.^[2][13] Denmark's pathways shortened the diagnostic interval, but people outside them were left behind.^[20]
• Make it easy to go back. Safety netting, meaning a clear plan for follow-up if symptoms persist, was recorded for only 44% of patients in England's 2014 audit.^[11] In the UK, about one in three adults aged 50 and over said worry about wasting the doctor's time would put them off.^[3]
• Measure and publish inequalities in the intervals. The gaps by age and ethnicity in repeat GP visits were present in 2010 and still visible in 2025.^[13][2] Routine, case-mix-adjusted reporting would show whether efforts to close them work.
• Treat hospital diagnostic capacity as a cancer priority. Between the ICBP jurisdictions, the diagnostic interval varied more than the primary care interval,^[1] and outcomes worsen with delays once a cancer has been diagnosed.^[19]
• Address the wider barriers in lower-resource settings. WHO's guide to early diagnosis asks programmes to identify barriers first, then work on community engagement, diagnostic and referral capacity, and timely access to treatment.^[6] Reviews from low- and middle-income countries point the same way.^[15][16]

Screening, which looks for cancer before symptoms appear, is a separate route and is covered in our study of screening uptake. All studies in this series are collected in the cancer research library.

Language: this piece says "people with cancer" and "people living with and after cancer", and describes the illness and its treatment plainly, without combat metaphors. Clinical terms such as "stage", "incidence" and "net survival" are used in the sense the cited source defines them.

Why we're publishing this

The time before a diagnosis is too often described as a person's own "delay". The evidence says something different. The longest waits cluster in particular cancers, particular groups and particular health systems, and in the international bowel cancer data the widest variation between countries was in the diagnostic interval, inside services. We are publishing this so that charities, support groups and campaigners can make that case with figures they can cite, and press for services that recognise cancer faster for everyone.

How to read this data

Most interval data come from surveys of people diagnosed with cancer and their doctors, sometimes linked to registry records. Surveys miss people who were too ill to respond or who had died, so they probably understate the longest journeys. The ICBP figures describe people diagnosed mostly in 2013–2015 in six high-income countries, not current waits or other countries. Intervals are reported as medians, the middle value, which says little about the people who wait longest.

England's survey data are deep but are one country's experience. The 2025 subgroup figures quoted here are unadjusted, so differences between groups partly reflect the mix of cancers in each group. The 2010 figures are adjusted and reported as odds ratios ("times the odds"), not risks. Evidence from low- and middle-income countries comes mostly from hospital-based studies of breast cancer, using inconsistent definitions. Links between time and outcomes come from observational studies: they show associations and cannot say what would have happened to any individual.

Use this data

Free to cite with attribution to Better Health For Everyone. Charities, campaigners and journalists are welcome to reuse these figures and charts. For the underlying figures as a spreadsheet, get in touch.

Important: This article summarises published research for general information. It is not medical advice and cannot be used to diagnose, treat or predict anything about an individual. If you have concerns about your own or someone else's health, please speak to a qualified health professional.

Sources

1. Weller D, Menon U, Zalounina Falborg A, et al. Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from the International Cancer Benchmarking Partnership (ICBP). BMJ Open, 2018. europepmc.org/article/MED/30482749
2. NHS England and Picker Institute Europe. National Cancer Patient Experience Survey 2025: national results and national data tables. NHS England, 2026. ncpes.co.uk/latest-national-results
3. Forbes LJ, Simon AE, Warburton F, et al. Differences in cancer awareness and beliefs between Australia, Canada, Denmark, Norway, Sweden and the UK (the International Cancer Benchmarking Partnership): do they contribute to differences in cancer survival? British Journal of Cancer, 2013. europepmc.org/article/MED/23370208
4. Weller D, Vedsted P, Rubin G, et al. The Aarhus statement: improving design and reporting of studies on early cancer diagnosis. British Journal of Cancer, 2012. europepmc.org/article/MED/22415239
5. Coxon D, Campbell C, Walter FM, et al. The Aarhus statement on cancer diagnostic research: turning recommendations into new survey instruments. BMC Health Services Research, 2018. europepmc.org/article/MED/30176861
6. World Health Organization. Guide to cancer early diagnosis. WHO, 2017. who.int/publications/i/item/9789241511940
7. Menon U, Vedsted P, Zalounina Falborg A, et al. Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP). BMJ Open, 2019. europepmc.org/article/MED/31776134
8. Vedsted P, Weller D, Zalounina Falborg A, et al. Diagnostic pathways for breast cancer in 10 International Cancer Benchmarking Partnership (ICBP) jurisdictions. BMJ Open, 2022. europepmc.org/article/MED/36521881
9. Menon U, Weller D, Falborg AZ, et al. Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP). British Journal of Cancer, 2022. europepmc.org/article/MED/35618787
10. Lyratzopoulos G, Abel GA, McPhail S, Neal RD, Rubin GP. Measures of promptness of cancer diagnosis in primary care: secondary analysis of national audit data on patients with 18 common and rarer cancers. British Journal of Cancer, 2013. europepmc.org/article/MED/23392082
11. Swann R, McPhail S, Witt J, et al. Diagnosing cancer in primary care: results from the National Cancer Diagnosis Audit. British Journal of General Practice, 2018. europepmc.org/article/MED/29255111
12. Murchie P, Adam R, McNair E, et al. Cancer diagnosis in Scottish primary care: results from the National Cancer Diagnosis Audit. European Journal of Cancer Care, 2020. europepmc.org/article/MED/32154635
13. Lyratzopoulos G, Neal RD, Barbiere JM, Rubin GP, Abel GA. Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience Survey in England. Lancet Oncology, 2012. europepmc.org/article/MED/22365494
14. Mendonca SC, Abel GA, Saunders CL, Wardle J, Lyratzopoulos G. Pre-referral general practitioner consultations and subsequent experience of cancer care: evidence from the English Cancer Patient Experience Survey. European Journal of Cancer Care, 2016. europepmc.org/article/MED/26227343
15. Petrova D, Garrido D, Špacírová Z, et al. Duration of the patient interval in breast cancer and factors associated with longer delays in low- and middle-income countries: a systematic review with meta-analysis. Psycho-Oncology, 2023. europepmc.org/article/MED/36345154
16. Subedi R, Houssami N, Nickson C, et al. Factors influencing the time to diagnosis and treatment of breast cancer among women in low- and middle-income countries: a systematic review. The Breast, 2024. europepmc.org/article/MED/38522173
17. Neal RD, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. British Journal of Cancer, 2015. europepmc.org/article/MED/25734382
18. Tørring ML, Falborg AZ, Jensen H, et al. Advanced-stage cancer and time to diagnosis: an International Cancer Benchmarking Partnership (ICBP) cross-sectional study. European Journal of Cancer Care, 2019. europepmc.org/article/MED/31119836
19. Hanna TP, King WD, Thibodeau S, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ, 2020. europepmc.org/article/MED/33148535
20. Jensen H, Tørring ML, Olesen F, et al. Diagnostic intervals before and after implementation of cancer patient pathways: a GP survey and registry based comparison of three cohorts of cancer patients. BMC Cancer, 2015. europepmc.org/article/MED/25900050
21. Jensen H, Vedsted P. Exploration of the possible effect on survival of lead-time associated with implementation of cancer patient pathways among symptomatic first-time cancer patients in Denmark. Cancer Epidemiology, 2017. europepmc.org/article/MED/28711854